Aug. 4 at 8:23 PM
$AUTL Tecartus still losing ground to AUTL. We need to get into the EU and take the rest of their B ALL business....
Tecartus (brexucabtagene autoleucel) sales decreased 24% year-over-year to
$70 million in Q2 2026, primarily due to in-class competition.
This is from Gilead Sciences’ Q2 2026 financial results (announced August 4, 2026). Key details:
Q2 2026 sales:
$70 million (vs.
$92 million in Q2 2025).
Breakdown (approximate from the product sales summary): U.S.
$29 million, Europe
$34 million, Rest of World
$8 million.
First-half 2026 sales:
$146 million (vs.
$171 million in the first half of 2025).
Overall Cell Therapy sales (Yescarta + Tecartus) fell 14% to
$417 million in the quarter, reflecting ongoing competitive headwinds. Yescarta specifically declined 12% to
$346 million due to in- and out-of-class competition.
